[Home](https://github.com/mm80843/T3.5/blob/pages/index.md) >> Class: [Benef](https://github.com/mm80843/T3.5/tree/main/docs/Benef/index.md) >> Individual ID:PBN__Benef_587 

# __Vaccine testing__

## Articles mentionning this Benefit

* [Current knowledge of COVID-19: Advances, challenges and future perspectives](https://github.com/mm80843/T3.5/blob/pages/Article/PBN__Article_118.md)

## Category to which it belongs

* [Expanded vaccination capabilities lead to improved healthcare capacity, equitable distribution, and enhanced response and technological capabilities.](https://github.com/mm80843/T3.5/blob/pages/PBNCategory/PBN__PBNCategory_31.md)

## Description of actual returns pertaining to this benefit

* [Asset value increase from improved testing and development](https://github.com/mm80843/T3.5/blob/pages/BenefReturn/PBN__BenefReturn_642.md)

## Name of the Benefit

Evaluation of vaccines and therapeutic drugs

## Risks which can benefit from this action

* [Animal models](https://github.com/mm80843/T3.5/blob/pages/Mitigation/PBN__Mitigation_591.md)

## Stakeholders benefitting from this Benefit

* [Researchers](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_2.md)

